Keyphrases
Preclinical Evaluation
100%
Multiple Myeloma
100%
Chimeric Antigen Receptor T Cells (CAR-T)
100%
Anti-B
100%
Structural Optimization
100%
Evaluation Optimization
100%
B-cell Maturation Antigen
100%
Antigen-specific
28%
Antitumoral Activity
28%
High Efficiency
14%
Cytotoxicity
14%
Malignancy
14%
Hematological Malignancies
14%
Clinical Trials
14%
Tumor Antigen
14%
Intracellular Domain
14%
Promising Treatment
14%
CD-8
14%
CD28
14%
Cytokine Production
14%
Activation Markers
14%
Receptor-based
14%
In Vivo Efficacy
14%
Targeting Moieties
14%
Marker Expression
14%
Target Activation
14%
IgG4-related Disease (IgG4-RD)
14%
CD19
14%
Critical Difference
14%
Primary T Cells
14%
Co-stimulatory Domain
14%
4-1BB
14%
T Cell Immunotherapy
14%
Exhaustion Marker
14%
Optimal Configuration
14%
Function Configuration
14%
Medicine and Dentistry
Multiple Myeloma
100%
Chimeric Antigen Receptor
100%
B Cell Maturation Antigen
100%
Immunotherapy
16%
In Vitro
16%
Cancer
16%
T Cell
16%
Peptide Sequence
16%
Cytotoxicity
16%
Clinical Trial
16%
Chimeric Antigen Receptor T-Cell
16%
CD8 Antigen
16%
Tumor Antigen
16%
Cytokine Production
16%
Hematologic Malignancy
16%
Immunoglobulin G4
16%
Immunology and Microbiology
Multiple Myeloma
100%
Chimeric Antigen Receptor
100%
B Cell Maturation Antigen
100%
T Cell
16%
Immunotherapy
16%
Amino Acid Sequence
16%
Cytotoxicity
16%
CD8
16%
Coculture
16%
Tumor Antigen
16%
Cytokine Production
16%
CD28
16%
CD19
16%
Immunoglobulin G4
16%
Chimeric Antigen Receptor T-Cell
16%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Myeloma
100%
Chimeric Antigen Receptor
100%
B Cell Maturation Antigen
100%
Immunotherapy
14%
Cytokine
14%
Hematologic Malignancy
14%
Clinical Trial
14%
Tumor Antigen
14%
CD8 Antigen
14%
Immunoglobulin G4
14%
Cytotoxicity
14%